Sen Sheng

Sen Sheng

Auto-generated profile, based on publicly available information

Sen Sheng

Neurology, University of Arkansas for Medical Sciences, Little Rock, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 February 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
YGYanfeng Gao
Yanfeng Gao
JWJinping Wang
Jinping Wang
YZYue Zhou
Yue Zhou
SSSen Sheng
Sen Sheng
SQSteven Qian
Steven Qian
XHXiongwei Huo
Xiongwei Huo
Blood-based protein biomarkers have recently shown as simpler diagnostic modalities for colorectal cancer, while their association with clinical pathological characteristics is largely unknown. In this study, we not only examined the sensitivity and reliability of single/multiple serum markers for diagnosis, but also assessed their connection with pathological parameters from a total of 279 colorectal cancer patients. Our study shown that glycoprotein carcinoembryonic antigen (CEA) owns the highest sensitivity among single marker in the order of CEA > cancer antigen 72-4 (CA72-4) > cancer antigen 19-9 9 (CA19-9) > ferritin > cancer antigen 125 (CA125), while the most sensitive combined-markers for two to five were: CEA + CA72-4; CEA + CA72-4 + CA125; CEA + CA19-9 + CA72-4 + CA125; and CEA + CA19-9 + CA72-4 + CA125 + ferritin, respectively. We also demonstrated that patients who had positive preoperative serum CEA, CA19-9, or CA72-4 were more likely with lymph node invasion, positive CA125 were prone to have vascular invasion, and positive CEA or CA125 were correlated with perineural invasion. In addition, positive CA19-9, CA72-4, or CA125 was associated with poorly differentiated tumor, while CEA, CA19-9, CA72-4, CA125 levels were positively correlated with pathological tumor-node-metastasis stages. We here conclude that combined serum markers can be used to not only diagnose colorectal cancer, but also appraise the tumor status for guiding treatment, evaluation of curative effect, and prognosis of patients.

1 February 2019 in Nitric Oxide
Verified
Journal Article
Closed access
YGYanfeng Gao
Yanfeng Gao
SZShuang Zhou
Shuang Zhou
YXYi Xu
Yi Xu
SSSen Sheng
Sen Sheng
SQSteven Qian
Steven Qian
XHXiongwei Huo
Xiongwei Huo

1 July 2019 in Journal of Clinical Neuroscience
Verified
Journal Article
Closed access
SSSen Sheng
Sen Sheng
LWLeihong Wu
Leihong Wu
KNKrishna Nalleballe
Krishna Nalleballe
RSRohan Sharma
Rohan Sharma
ABAliza Brown
Aliza Brown
SOSanjeeva Onteddu
Sanjeeva Onteddu

1 January 2018 in International Journal of Biological Sciences
Verified
Journal Article
Open access
YGYanfeng Gao
Yanfeng Gao
SZShuang Zhou
Shuang Zhou
FWFengfei Wang
Fengfei Wang
YZYue Zhou
Yue Zhou
SSSen Sheng
Sen Sheng
XHXiongwei Huo
Xiongwei Huo
The most effective way of treating liver cancer is surgical resection, which usually requires blocking the hepatic portal circulation, and may result in hepatic ischemia-reperfusion injury (HIRI). It is of paramount importance to control HIRI for liver cancer surgical resection. In this study, a 70% ischemic reperfusion (I/R) model of rat liver was established, and the protective effect and mechanism of limb ischemic post-conditioning (LIPOC) on HIRI was investigated. We show that LIPOC has a protective effect on hepatic ischemia-reperfusion injury in rats, which reduces the elimination of superoxide dismutase, thereby increasing oxygen free radical scavenging, decreasing lipid peroxidation, inhibiting neutrophil aggregation, as well as reducing TNFα, IL1β, and other inflammatory cytokines. In addition, LIPOC inhibited the apoptosis of hepatocytes induced by I/R injury, and decreased the Bax/Bcl-2 ratio. Furthermore, LIPOC promoted the phosphorylation of Akt and ERK1/2. The use of PI3K inhibitor LY294002 and ERK1/2 blocker PD98059 inhibited the phosphorylation of Akt and ERK1/2 caused by LIPOC and abolished the injury protection of liver I/R. Moreover, through 16 cases of hepatocellular carcinoma resections, we found that short-term LIPOC treatment significantly suppressed the elevated alanine aminotransferase, aspartic transaminase, and total bilirubin in the early post-operation of liver resection, and reduced reperfusion injury to the ischemic liver. In summary, our study demonstrated that LIPOC could be an effective method for HIRI in the clinical implementation of liver resection and uncovered the potential mechanism of LIPOC in the protective effects of HIRI.

22 March 2022 in Healthcare
Verified
Journal Article
Open access
PDF file
HEHisham Elkhider
Hisham Elkhider
RSRohan Sharma
Rohan Sharma
SSSen Sheng
Sen Sheng
JTJeff D Thostenson
Jeff D Thostenson
NKNidhi Kapoor
Nidhi Kapoor
KNKrishna Nalleballe
Krishna Nalleballe
In this study, we aim to identify predictors of a no-show in neurology clinics at our institution. We conducted a retrospective review of neurology clinics from July 2013 through September 2018. We compared odds ratio of patients who missed appointments (no-show) to those who were present at appointments (show) in terms of age, lead-time, subspecialty, race, gender, quarter of the year, insurance type, and distance from hospital. There were 60,012 (84%) show and 11,166 (16%) no-show patients. With each day increase in lead time, odds of no-show increased by a factor of 1.0019 (p < 0.0001). Odds of no-show were higher in younger (p ≤ 0.0001, OR = 0.49) compared to older (age ≥ 60) patients and in women (p < 0.001, OR = 1.1352) compared to men. They were higher in Black/African American (p < 0.0001, OR = 1.4712) and lower in Asian (p = 0.03, OR = 0.6871) and American Indian/Alaskan Native (p = 0.055, OR = 0.6318) as compared to White/Caucasian. Patients with Medicare (p < 0.0001, OR = 1.5127) and Medicaid (p < 0.0001, OR = 1.3354) had higher odds of no-show compared to other insurance. Young age, female, Black/African American, long lead time to clinic appointments, Medicaid/Medicare insurance, and certain subspecialties (resident and stroke clinics) are associated with high odds of no show. Possible suggested interventions include better communication and flexible appointments for the high-risk groups as well as utilizing telemedicine.

1 April 2020 in Stroke
Verified
Journal Article
Closed access
PDF file
KNKrishna Nalleballe
Krishna Nalleballe
SSSen Sheng
Sen Sheng
CLChenghui Li
Chenghui Li
RMRuchira Mahashabde
Ruchira Mahashabde
AAAmarnath R. Annapureddy
Amarnath R. Annapureddy
SOSanjeeva Onteddu
Sanjeeva Onteddu
Background and Purpose—: Industry payments to physicians raise concerns regarding conflicts of interest that could impact patient care. We explored nonresearch and nonownership payments from industry to vascular neurologists to identify trends in compensation. Methods—: Using Centers for Medicare and Medicaid Services and American Board of Psychiatry and Neurology data, we explored financial relationships between industry and US vascular neurologists from 2013 to 2018. We analyzed payment characteristics, including payment categories, payment distribution among physicians, regional trends, and biomedical manufacturers. Furthermore, we analyzed the top 1% (by compensation) of vascular neurologists with detailed payment categories, their position, and their contribution to stroke guidelines. Results—: The number of board certified vascular neurologist increased from 1169 in 2013 to 1746 in 2018. The total payments to vascular neurologist increased from $99 749 in 2013 to $1 032 302 in 2018. During the study period, 16% to 17% of vascular neurologists received industry payments. Total payments from industry and mean physician payments increased yearly over this period, with consulting fee (31.1%) and compensation for services other than consulting (30.7%) being the highest paid categories. The top 10 manufacturers made the majority of the payments, and the top 10 products changed from drug or biological products to devices. Physicians from south region of the United States received the highest total payment (38.72%), which steadily increased. Payments to top 1% vascular neurologists increased from 64% to 79% over the period as payments became less evenly distributed. Among the top 1%, 42% specialized in neuro intervention, 11% contributed to American Heart Association/American Stroke Association guidelines, and around 75% were key leaders in the field. Conclusions—: A small proportion of US vascular neurologists consistently received the majority of industry payments, the value of which grew over the study period. Only 11% of the top 1% receiving industry payments have authored American Heart Association/American Stroke Association guidelines, but ≈75% seem to be key leaders in the field. Whether this influences clinical practice and behavior requires further investigation.